Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma
Endometrial carcinoma is the most common malignant tumor of the female genital tract in the United States. Epigenetic alterations are implicated in endometrial cancer development and progression. Histone deacetylase inhibitors are a novel class of anticancer drugs that increase the level of histone...
Guardado en:
Autores principales: | Iason Psilopatis, Alexandros Pergaris, Constantinos Giaginis, Stamatios Theocharis |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Hindawi Limited
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/31562f8e58064522ad9bb95f1f581b82 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
High Pregnane X Receptor (PXR) Expression Is Correlated with Poor Prognosis in Invasive Breast Carcinoma
por: Stamatios Theocharis, et al.
Publicado: (2021) -
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
por: Ververis K, et al.
Publicado: (2013) -
Antitheilerial Activity of the Anticancer Histone Deacetylase Inhibitors
por: Madhumanti Barman, et al.
Publicado: (2021) -
Starch nanoparticles for delivery of the histone deacetylase inhibitor CG-1521 in breast cancer treatment
por: Alp E, et al.
Publicado: (2019) -
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma
por: Tandon N, et al.
Publicado: (2016)